Integrated Wealth Concepts LLC Has $8.87 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Integrated Wealth Concepts LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,943 shares of the company’s stock after purchasing an additional 1,573 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Johnson & Johnson were worth $8,865,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. RE Dickinson Investment Advisors LLC raised its position in Johnson & Johnson by 163.3% in the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after purchasing an additional 98 shares during the last quarter. Morton Brown Family Wealth LLC raised its position in Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares during the last quarter. Advanced Research Investment Solutions LLC raised its position in Johnson & Johnson by 200.0% in the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after purchasing an additional 120 shares during the last quarter. Professional Financial Advisors LLC raised its position in Johnson & Johnson by 47.9% in the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after purchasing an additional 68 shares during the last quarter. Finally, Goodman Advisory Group LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at $39,000. Institutional investors and hedge funds own 68.59% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at $18,864,202. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider William Hait sold 15,000 shares of the company’s stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the sale, the insider now owns 80,236 shares in the company, valued at $13,764,485.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Peter Fasolo sold 22,864 shares of the company’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the sale, the vice president now owns 114,676 shares in the company, valued at approximately $18,864,202. The disclosure for this sale can be found here. Insiders sold 118,795 shares of company stock valued at $20,230,174 over the last three months. Company insiders own 0.35% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on JNJ. Barclays began coverage on Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective for the company. Bank of America dropped their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Sanford C. Bernstein dropped their target price on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Morgan Stanley dropped their target price on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 19th. Finally, Citigroup dropped their target price on Johnson & Johnson from $201.00 to $198.00 in a research report on Wednesday, October 5th. Six analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $184.25.

Johnson & Johnson Stock Up 0.3 %

NYSE:JNJ opened at $172.39 on Wednesday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The stock has a market cap of $450.71 billion, a price-to-earnings ratio of 24.01, a PEG ratio of 3.35 and a beta of 0.57. The stock has a 50-day moving average price of $167.25 and a two-hundred day moving average price of $171.38.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. During the same period in the previous year, the firm earned $2.60 earnings per share. The company’s revenue was up 1.9% on a year-over-year basis. As a group, equities analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson announced that its board has initiated a stock repurchase program on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the company to buy up to 1.2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 annualized dividend and a dividend yield of 2.62%. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.